ESMO Preceptorship on NSCLC Singapore December 2016

Oncology Meeting Resources

13 Dec - 14 Dec, Singapore, Singapore

ESMO Preceptorship

Main learning objectives for the ESMO Preceptorship on NSCLC Singapore 2016 included learning about best clinical practice in the management of Non-Small-Cell Lung Cancer (NSCLC) in the adjuvant, locally advanced and metastatic setting; understanding the importance of pathology and histoprognostic factors in the management of NSCLC and learning about the management of patients after progression, side-effects of treatments, and the use of targeted agents in NSCLC

Presentations from the Preceptorship are now available here. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful Links

Presenter Presentation title Session title
K. Kerr, UK Histopathology of NSCLC, IHC Markers and pTNM Classification Session 1 Non Metastatic Disease
D. Grunenwald, FR State of the Art: Standard of Care for Resectable NSCLC: Surgical Approach for Resectable NSCLC Session 1 Non Metastatic Disease
J. Bennouna, FR State of the Art: Standard of Care For Resectable NSCLC: Adjuvant Chemotherapy; Is There a Place for Neo Adjuvant Chemotherapy? Session 1 Non Metastatic Disease
J-Y. Douillard, CH Radiotherapy in NSCLC: What Are The ESMO Guidelines? The Role of Radiation in Early Stage; RT/CT for Unresectable NSCLC; Brain Metastasis; Oligometastatic Disease Session 1 Non Metastatic Disease
A. Anand, IN Recurrent NSCLC after Treatment for Early Stage Disease - Role of Maintenance Therapy Session 2 Audience Cases
V. Kuriakose, IN Significance of EGFR Mutation Analysis in the NSCLC Apecimen in a Nonmetastatic Setting Session 2 Audience Cases
D. Kumar, IN Case Study Session 2 Audience Cases
Y-L. Wu, CN 1st Line Chemotherapy and Contribution of Targeted Agents Session 3 Metastatic NSCLC
E. F.Smit, NL Maintenance Treatment: Chemo Maintenance or Targeted Agents or Both? Session 3 Metastatic NSCLC
J. Bennouna, FR Biomarker Driven Treatment of Selected NSCLC: EGFR. EGFR TKI in Mutant EGFR NSCLC. Mechanisms of Resistance and New Generation EGFR TKI. Session 4 Biomarker Driven Treatment
E. Iwama, JP Tissue or Liquid Biopsies? For Diagnosis, Monitoring and Early Detection of Resistance Session 4 Biomarker Driven Treatment
K. Nakagawa, JP Biomarker Driven Treatment of Selected NSCLC: ALK EML4; Crizotinib; Crizotinib Resistance; 2nd Generation Drugs Session 4 Biomarker Driven Treatment
N. Shariff, MY T790M Mutated Lung Adenocarcinoma Session 5 Audience Cases
B. Biswas, IN Metastatic Adenocarcinoma of Lung: Mutational Analysis from Pleural Fluid Cytology and its Therapeutic Implication Session 5 Audience Cases
T. Rajasekaran, SG Metastatic NSCLC Session 5 Audience Cases